Sponsor
InCor Heart Institute
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name InCor Heart Institute appears in 24 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
24 shownCardiac Contractility Modulation in Chagas Heart DiseaseNCT05519046 · lead sponsor · 2022-05-25
RECRUITINGEffect of a Low Advanced Glycation End Products Diet of Patients With Type 2 Diabetes MellitusNCT07303842 · lead sponsor · 2022-03-08
COMPLETEDMinimizing Contrast Utilization With IVUS Guidance in Coronary Angioplasty to Avoid Acute NephropathyNCT02743156 · lead sponsor · 2016-04-01
UNKNOWNCharacterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and AngiomyolipomaNCT02325505 · lead sponsor · 2016-04-01
COMPLETEDEvaluation of Exercise Capacity and Exercise Limitation in Patients With Pulmonary Langerhans Cell HistiocytosisNCT02665546 · lead sponsor · 2016-03-01
COMPLETEDRenal Denervation in Patients With Heart Failure With Normal LV Ejection FractionNCT02115230 · lead sponsor · 2014-04-01
UNKNOWNRenal Denervation in Patients With Heart Failure Secondary to Chagas DiseaseNCT02099903 · lead sponsor · 2014-03-01
UNKNOWNEffects of Air Pollution Exposure Reduction by Filter Mask on Heart FailureNCT01960920 · lead sponsor · 2013-02-01
COMPLETEDPeripherally Inserted Central Catheter Use for Dobutamine Infusion in Heart Failure PatientsNCT02854254 · lead sponsor · 2012-12-01
UNKNOWNIVUS Guidance to Reduce Contrast in Coronary AngioplastyNCT01947335 · lead sponsor · 2012-11-01
COMPLETEDEvaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung PerfusionNCT01353105 · lead sponsor · 2011-08-01
UNKNOWNLosartan in Decompensated Heart FailureNCT01857999 · lead sponsor · 2008-09-01
COMPLETEDCreatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation TherapyNCT07463092 · collaborator · 2026-05-01
RECRUITINGTechnological Innovation in the Virtual Assistance of Patients With Uncontrolled Arterial Hypertension - Hyper 2NCT05843682 · collaborator · 2022-10-07
UNKNOWNPentoxifylline as an Adjunct Therapy for Patients With Eisenmenger SyndromeNCT05611268 · collaborator · 2022-06-03
UNKNOWNThe Impact of Chronic Mitochondrial Antioxidant Supplementation on CardiovascularToxicity in Breast Cancer PatientsNCT05146843 · collaborator · 2022-06-02
UNKNOWNAngiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.NCT04853758 · collaborator · 2021-05-06
UNKNOWNCryotherapy Versus Radiofrequency Ablation for Treatment of Para-hisian Accessory PathwaysNCT04361006 · collaborator · 2018-10-01
COMPLETEDEffects of a Home-based Exercise Program on Functional Capacity and Quality of Life in Heart Failure PatientsNCT03615157 · collaborator · 2018-01-15
UNKNOWNDPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet FunctionNCT02377388 · collaborator · 2017-02-07
COMPLETEDEffect of Physical Training in Patients With Heart Failure Caused by Chemotherapy for Cancer TreatmentNCT04047901 · collaborator · 2016-11-07
UNKNOWNPrognostic Value of Sympathetic Modulation in Patients With Heart FailureNCT02047409 · collaborator · 2013-10-01
UNKNOWNExercise Improve Sympathetic Modulation in Chronic Heart Failure PatientsNCT02219451 · collaborator · 2013-08-01
COMPLETEDProgram for Health Promotion to Improve Therapeutic Compliance in Hypertensive PatienteNCT02036814 · collaborator · 2007-03-01
COMPLETEDDrugs studied in this sponsor's trials
5 mapped RxNorm conceptsThese drug records are connected through ClinicalTrials.gov studies listing InCor Heart Institute as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.
placebo2
enalapril1
losartan1
pentoxifylline1
sacubitril / valsartan Oral Tablet [Entresto]1
placebo RxCUI 8375 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
2 trials
enalapril RxCUI 3827 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
losartan RxCUI 52175 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
pentoxifylline RxCUI 8013 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
sacubitril / valsartan Oral Tablet [Entresto] RxCUI 1656343 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
Sponsor roles
collaborator12
lead sponsor12
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.